Audenz (CSL Seqirus) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F
Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Audenz Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.
The audenz market has experienced significant growth due to various global health factors. Historical growth was driven by past avian influenza outbreaks, government initiatives for pandemic preparedness, advancement in MF59 adjuvant technology, public sector vaccine procurement, and global infectious disease surveillance.
Looking ahead, the forecast predicts continued growth fueled by rising risks of zoonotic infections, the expansion of national stockpiles, increased funding for pandemic vaccines, enhanced global health collaborations, and improved adult immunization strategies.
Key trends shaping the audenz market include a heightened focus on pandemic preparedness vaccines, increased adoption of adjuvanted influenza vaccines, expansion of stockpiling for emerging threats, and the strengthening of government-led immunization programs. There is also a notable emphasis on improving vaccine efficacy for high-risk populations.
The prevalence of influenza significantly drives audenz market growth, with the H5N1 subtype posing considerable health risks. The global spike in influenza cases can be attributed to evolving viral strains, dense populations, and inadequate preventive care in certain regions. Audenz, specifically targeting the H5N1 strain, is crucial for preventing influenza outbreaks, reducing severe illnesses, and lowering mortality rates.
Personalized medicine, tailoring treatments based on genetic and environmental factors, propels the audenz market further. With advances in genomic technologies, there is a growing demand for personalized approaches that enable precise risk assessment and treatment strategies. Audenz aligns well with personalized medicine by offering strain-specific protection against H5N1, especially valuable for populations at heightened risk of severe complications. Rising healthcare expenditure is another key factor boosting the audenz market, with increased spending facilitating broader immunization coverage, supporting vaccine research, and reducing influenza-related healthcare costs.
In 2025, North America led the audenz market, with Asia-Pacific anticipated to grow the fastest in the forecast period. The regions covered include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Tariffs have impacted the market by increasing costs related to imported vaccine materials, particularly affecting regions reliant on cross-border supply chains like Asia-Pacific and parts of Europe. However, tariffs have also encouraged localized vaccine production, strengthening long-term supply security for pandemic vaccines.
Major players in the audenz market include CSL Seqirus. The market consists of sales of vaccines for immunization against the H5N1 influenza virus. Values reflect factory gate price points, encompassing sales to various entities and end customers. The audenz market research report provides an in-depth analysis of market statistics, trends, and opportunities, offering a comprehensive view of the industry, including its current and future scenarios.
Report Scope
Major Trends
For more information about this report visit https://www.researchandmarkets.com/r/t2o7l5
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.